Global Regenerative Medicines Market - Analysis and Forecast (2017-2025)

Market Overview

The increased prevalence of chronic and genetic diseases has led to the high demand for better medicines. The existing therapies mostly treat the symptoms of the disease. But there was an impending need to identify the root-causes of any disease and then treat it accordingly. This need was effectively met with the advent of regenerative medicines in the medical world. Regenerative medicine is defined as the therapy involving the replacement or repair of the damaged tissue or organs, thereby completely curing the disease. The discovery of stem cells, the development of laboratory culture techniques, and the characterisation of pluripotent, and different stem cell types have together led to the development of regenerative medicine.

Regenerative medicine represents a new paradigm in human health, with the potential to resolve unmet medical needs by addressing the underlying causes of disease. Regenerative medicine research translates fundamental knowledge in biology, chemistry and physics into materials, devices, systems and a variety of therapeutic strategies which augment, repair, replace or regenerate organs and tissues. This rapidly evolving, interdisciplinary field in healthcare is transforming the practice of medicine, medical innovation and the production of medical devices and therapies. 

The regenerative medicines market generated $17.03 billion revenue in 2016. The North America regenerative medicines market currently holds 39% percent of the global regenerative medicines market. Technological innovations across the various segments of the regenerative medicine have propelled growth in the recent past in the region. The global regenerative medicines market is expected to reach $50.55 billion by 2025. The rapid expansion of the stem cell and gene therapy in the developed markets such as the U.S., Japan, Germany, and the U.K. is key driver for growth of regenerative medicines market.

As the world population is aging at a much faster pace, and the prevalence of diseases is rising, the demand is increasing for regenerative medicines that not only cure the chronic conditions completely but also improve the quality of life of the patients. Other factors contributing to the growth of the regenerative medicine market include the rising awareness about regenerative medicine, technological advancements, and better efficacy, and safety provided by such products. The major challenge to the growth of the market constitutes the changing regulatory environment. The stringent regulations implemented by the concerned regulatory bodies for the regenerative medicine products is a challenging factor for the industry players.

The regenerative medicines market, cumulative of tissue engineering products, gene therapy, and stem cell therapy is fragmented in nature due to the involvement of numerous global as well as regional players (700+) in this industry. Most of the companies in this sector are in clinical stage and are expected to launch their products in the coming few years.

The global regenerative medicines market is generally dominated by the global orthopedic and wound biologics companies, however, depending on the geographical areas the market of these players varies accordingly. Efficient distribution networks, product differentiation and supply competency play a major role in determining the market position of such players. Majority of these players are focusing on expanding distribution network as well as expanding presence, as Asia Pacific, Latin America and the Middle East are the developing regions and there is an increasing awareness about tissue and cell based products.

The global regenerative medicine market on the basis of therapy can be segmented into cell therapy, gene therapy, and tissue engineering. The major contributor towards the market in 2016 was tissue engineering market with an estimated value of $10.78 billion in 2016. Based on the application type, the market is segmented into orthopaedic, cardiovascular, wound healing, diabetes, immune-oncology, and others. Moreover, based on the product type, the market can be segmented into cellular, and acellular products. Geographically, the largest contributor to the growth of the global regenerative medicine market was North America, attributing to the presence of various biopharmaceutical companies involved in R&D of regenerative products in the region followed by Europe. The highest CAGR was observed for Asia-pacific region due to encouraging regulatory decisions for regenerative medicine such as in Japan.

Regenerative medicine cures the disease at the root cause, thus offering permanent treatment, unlike the palliative treatment offered by pharmaceutical products. The possibility of the development of a therapy for the treatment of rare, and orphan diseases, use of nanomaterials, and the recent development of cell free therapy, stem cell exosomes, present opportunities for the further growth of the global regenerative medicine market. 

The report provides in-depth SWOT analysis of different key players of the market, supported by an extensive financial summary of each. Some of the key players are Novartis AG, ViaCyte, Inc., Vericel Corporation, Tissue Regenix, Osiris Therapeutics, Inc., NuVasive, Inc., MiMedx Group Inc., Mesoblast Limited, Acelity, and Cytori Therapeutics.